Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway
anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway
infection. It is hypothesized that steady-state levels of KB001-A in CF subjects with airway
Pa infection will be safe and well-tolerated, and will increase the time-to-need for
antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and
symptoms compared with placebo.